TCM
ARLZ

Teza Capital Management’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Teza Capital Management’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-10,094
Closed -$22K – 493
2017
Q1 		$22K Buy
+10,094
New +$37.9K 0.01% 498

Other funds holding ARLZ

PCM
PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return

Teza Capital Management's ARLZ Position: Q2 2017 in Review

Teza Capital Management sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q2 2017, closing a stake of 10,094 shares — an estimated $22K sold.

Teza Capital Management first reported a position in ARLZ in Q1 2017 and held it in 1 quarter. The position peaked at $22K in Q1 2017. 72 funds tracked by Wall St. Rank hold ARLZ as of Q2 2017.

  • Teza Capital Management reported no remaining Aralez Pharmaceuticals Inc. position as of Q2 2017 after selling out during the quarter.
  • Teza Capital Management sold 10,094 Aralez Pharmaceuticals Inc. shares in Q2 2017, an estimated $22K.
  • Teza Capital Management first reported a position in Aralez Pharmaceuticals Inc. in Q1 2017 and held it in 1 quarter.
  • Teza Capital Management's Aralez Pharmaceuticals Inc. position peaked at $22K in Q1 2017.
  • 72 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q2 2017.

Based on Teza Capital Management's 13F filing for Q2 2017.